Antiplatelet Resistance in Patients Who Underwent Coronary Artery Bypass Grafting: A Systematic Review and Meta-Analysis

Use of antiplatelet medication following coronary artery bypass grafting is common practice to reduce thrombotic events. However, antiplatelet resistance is of growing concern. The authors of this review conducted a systematic review and meta-analysis of eleven studies involving 3122 patients. The primary outcome measures were major adverse cardiovascular events and mortality. The authors report a 39 percent prevalence of antiplatelet resistance from the studies included.